GAMMA Investing LLC Has $644,000 Holdings in Liquidia Technologies, Inc. (NASDAQ:LQDA)

GAMMA Investing LLC raised its position in Liquidia Technologies, Inc. (NASDAQ:LQDA - Free Report) by 2,342.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 43,675 shares of the company's stock after buying an additional 41,887 shares during the period. GAMMA Investing LLC owned 0.05% of Liquidia Technologies worth $644,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC acquired a new position in shares of Liquidia Technologies in the 4th quarter worth approximately $59,000. Summit Investment Advisors Inc. raised its position in Liquidia Technologies by 35.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock valued at $78,000 after purchasing an additional 1,719 shares during the last quarter. D. E. Shaw & Co. Inc. acquired a new position in Liquidia Technologies in the fourth quarter worth $142,000. EntryPoint Capital LLC bought a new stake in shares of Liquidia Technologies during the fourth quarter worth $154,000. Finally, Bayesian Capital Management LP bought a new stake in shares of Liquidia Technologies during the fourth quarter worth $163,000. 64.54% of the stock is owned by institutional investors.

Insider Activity at Liquidia Technologies

In other Liquidia Technologies news, insider Rajeev Saggar sold 2,450 shares of the company's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $13.67, for a total value of $33,491.50. Following the transaction, the insider now directly owns 263,152 shares of the company's stock, valued at $3,597,287.84. This represents a 0.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Jason Adair sold 1,856 shares of the stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $25,185.92. Following the transaction, the insider now owns 184,304 shares in the company, valued at $2,501,005.28. The trade was a 1.00% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 33,138 shares of company stock valued at $450,233. 26.50% of the stock is owned by insiders.

Liquidia Technologies Trading Up 0.4%

Shares of NASDAQ:LQDA traded up $0.05 during midday trading on Thursday, hitting $13.64. The company had a trading volume of 1,463,501 shares, compared to its average volume of 1,214,854. The company has a current ratio of 2.93, a quick ratio of 2.91 and a debt-to-equity ratio of 2.08. Liquidia Technologies, Inc. has a 12 month low of $8.26 and a 12 month high of $19.41. The firm has a fifty day simple moving average of $15.24 and a 200 day simple moving average of $14.17. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -8.63 and a beta of 0.04.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.03). Liquidia Technologies had a negative return on equity of 177.91% and a negative net margin of 903.80%. The firm had revenue of $3.12 million during the quarter, compared to analyst estimates of $3.23 million. On average, analysts predict that Liquidia Technologies, Inc. will post -1.51 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on LQDA shares. Scotiabank upped their price target on shares of Liquidia Technologies from $36.00 to $37.00 and gave the stock a "sector outperform" rating in a research report on Wednesday, May 28th. Oppenheimer set a $13.00 target price on shares of Liquidia Technologies and gave the stock an "underperform" rating in a research note on Monday, May 19th. Needham & Company LLC reissued a "buy" rating on shares of Liquidia Technologies in a research note on Monday, June 2nd. Wall Street Zen raised shares of Liquidia Technologies from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, Wells Fargo & Company upped their price objective on Liquidia Technologies from $23.00 to $25.00 and gave the stock an "overweight" rating in a report on Thursday, June 12th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $26.89.

About Liquidia Technologies

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).